Variations in the management of fibromyalgia by physician specialty: rheumatology versus primary care

Stephen L Able
Rebecca L Robinson
Kurt Kroenke
Philip Mease
David A Williams
Yi Chen
Madelaine Wohlreich
Bill H McCarberg

Purpose: To evaluate the effect of physician specialty regarding diagnosis and treatment of fibromyalgia (FM) and assess the clinical status of patients initiating new treatment for FM using data from Real-World Examination of Fibromyalgia: Longitudinal Evaluation of Costs and Treatments.

Patients and methods: Outpatients from 58 sites in the United States were enrolled. Data were collected via in-office surveys and telephone interviews. Pairwise comparisons by specialty were made using chi-square, Fisher’s exact tests, and Student’s t-tests.

Results: Physician specialist cohorts included rheumatologists (n=54), primary care physicians (n=25), and a heterogeneous group of physicians practicing pain or physical medicine, psychiatry, neurology, obstetrics and gynecology, osteopathy, or an unspecified specialty (n=12). The rheumatologists expressed higher confidence diagnosing FM (4.5 on a five-point scale) than primary care physicians (4.1) (P=0.037). All cohorts strongly agreed that recognizing FM is their responsibility. They agreed that psychological aspects of FM are important, but disagreed that symptoms are psychosomatic. All physician cohorts agreed with a multidisciplinary approach including nonpharmacological and pharmacological treatments, although physicians were more confident prescribing medications than alternative therapies. Most patients reported moderate to severe pain, multiple comorbidities, and treatment with several medications and nonpharmacologic therapies.

Conclusion: Physician practice characteristics, physician attitudes, and FM patient profiles were broadly similar across specialties. The small but significant differences reported by physicians and patients across physician cohorts suggest that despite published guidelines, treatment of FM still contains important variance across specialties.

Keywords: medical specialty, treatment, prospective observational study

Introduction
Fibromyalgia (FM) is a chronic pain condition, characterized by numerous associated symptoms (eg, widespread pain, fatigue, sleep disturbances, dyscognition), many of which may also be shared with other disorders. A patient satisfies the diagnostic criteria for FM if the following conditions are met: widespread pain index ≥7 and symptom severity scale score ≥5, or widespread pain index 3–6 and symptom severity scale score ≥9; symptoms have been present at a similar level for at least 3 months; and the patient does not have a disorder that would otherwise explain the pain. Diagnosis of FM is dependent upon patients’ reporting of symptoms as there is no objective clinical finding or single widely accepted test with which to confirm diagnosis or gauge the severity of symptoms. As with many forms of chronic pain, there are multiple treatment approaches including nonpharmacological and pharmacological treatments, although physicians were more confident prescribing medications than alternative therapies.
approaches that can be considered, and the clinician often matches the appropriate treatment strategy with the needs of the individual patient. Historically, the management of FM has been heavily concentrated within the purview of rheumatologists (RHMs); more recently, however, a wider range of physician specialists are being consulted by individuals with FM (eg, primary care physicians [PCPs], psychiatrists, and neurologists). With accumulating evidence that FM is a disorder of central pain processing/modulation, FM can no longer be categorized as a musculoskeletal disease process, but rather as a pain syndrome maintained by perturbed central nervous system activity.4,5

A recent prospective observational study, the Real-World Examination of Fibromyalgia: Longitudinal Evaluation of Costs and Treatments (REFLECTIONS), was designed to describe burden of illness and treatment patterns in individuals with FM within “real-world” practice settings.6 Descriptive analyses of baseline data from the REFLECTIONS study confirmed that the burden of illness was high for patients with FM, and treatment patterns revealed the use of a wide variety of medications (both US Food and Drug Administration [FDA]-approved and off-label) and a broad sampling of nonpharmacologic treatments often used in combination with medications. Multivariate patient-focused analyses of the REFLECTIONS baseline data comparing the use of FDA-approved medications (eg, duloxetine, pregabalin, and milnacipran) with other medications for the treatment of FM showed physician specialty to be among the strongest determinants of which FM treatment was selected.

The primary purpose of this post hoc analysis was to describe differences between specialties, primarily those from rheumatology and primary care, in: 1) physician and physician-practice characteristics; 2) physician attitudes and beliefs regarding diagnosis and treatment of FM; and 3) physician prescribing behavior as manifested in actual treatment patterns. A secondary purpose of the study was to examine differences in the demographic and clinical profiles of patients treated by physicians from the studied specialties.

Material and methods
The following is a summary of methodological considerations from the REFLECTIONS study that were deemed pertinent to the understanding of the present manuscript. A more complete description of the REFLECTIONS study methodology is provided in Robinson et al.6 The protocol for the REFLECTIONS study was approved by Schulman’s Institutional Review Board. All patients provided written informed consent before participating in the study.

Study setting
REFLECTIONS was an observational, multicenter, real-world study, in which all treatment occurred as part of routine care provided in the course of normal clinical practice. The study included 91 study investigators from 58 practice-based settings in the United States and Puerto Rico. Potential investigators were identified through lists of investigators with prior experience conducting observational or clinical research; literature searches of physician authors publishing in FM; and referrals from other physicians. Physicians were invited to participate as study investigators on the basis of the average number of patients with FM they saw monthly. Physician recruitment was monitored in an attempt to ensure that the distribution of study physicians reflected the types and rates of physicians seen in actual clinical practice.

A total of 54 physicians practicing rheumatology (RHMs) enrolled 1,130 patients, 25 physicians practicing primary care medicine (PCPs) enrolled 271 patients, and a heterogeneous group of 12 physicians practicing either pain or physical medicine (n=3), psychiatry (n=3), neurology (n=2), obstetrics and gynecology (n=1), osteopathy (n=1), or an unspecified specialty (n=2) (OTHERs) enrolled the remaining 299 patients. Enrollment for RHMs (20.9) and OTHERs (24.9) was approximately twice as many patients-per-physician than enrollment for PCPs (10.8). Due to the small sample size (n=12) and heterogeneity of physicians in the group of OTHERs, the results from the OTHERs may preclude meaningful interpretation.

Inclusion/exclusion criteria
Patients were eligible for REFLECTIONS if they were at least 18 years of age, cognitively able to understand and complete computer-assisted telephone interviews in English or Spanish, and available to participate in the study for 12 months. Patients were invited to participate if, in the opinion of the enrolling physician, they: 1) met diagnostic criteria for FM; 2) were initiating a new treatment for FM; and 3) were under the care of the participating physician at the time of enrollment. New treatment for FM was defined as a prescription for any pharmacologic agent used for the treatment of FM that had not been used in the last 6 months, and thus comprised naïve FM treatment initiators, patients switching from one treatment to another, and patients aug-
menting an existing treatment regimen. Individuals who were investigators or site personnel directly affiliated with the study, and/or their immediate families, were excluded from the study.

Data collection
Data were collected by three separate means: a physician survey completed prior to the enrollment of any patients; a patient visit form completed jointly by the patient and physician or practice staff member during the enrollment visit (after the patient had signed the patient informed consent form); and structured interviews conducted with patients via telephone (to collect additional data regarding patient health status and care at baseline and throughout the 12 months of the study) following the enrollment visit. The physician survey provided information regarding physician demographics, practice characteristics, and physician attitudes and opinions regarding the diagnosis and treatment of FM. These attitudes and opinions were assessed by asking physicians to indicate their level of agreement with a battery of statements using a five-point scale (1 = completely disagree, 2 = somewhat disagree, 3 = neither agree nor disagree, 4 = somewhat agree, or 5 = completely agree). The physician survey was specifically created to provide descriptive information for use in the REFLECTIONS study.

The patient visit form was completed jointly by the physician and the patient during the routine office visit when a new pharmacologic treatment was prescribed. Study investigators provided an assessment of each enrolled patient’s medical history and treatment plan, including all ongoing, discontinued, and newly started pharmacologic and nonpharmacologic therapies for FM. Patients added their demographic information and a portion of their medical history using the Patient Health Questionnaire-15 to complete the office visit form. No further study-specific physician or on-site patient information was required.

Baseline and follow-up data were used to conduct the longitudinal portion of the primary REFLECTIONS analyses reported in Robinson et al. Only baseline information, which was gathered within 14 days of study enrollment, was utilized in the analyses reported in this manuscript.

Statistical analysis
Descriptive statistics were used to characterize current treatment patterns and other patient and physician variables. Means and standard deviations were reported for continuous variables for each of the three specialist groupings; proportions were reported for categorical variables. Pairwise comparisons between physician specialist categories were made using chi-square and Fisher’s exact tests for categorical variables and Student’s t-tests for continuous variables. No adjustments were made for multiple comparisons, as the study objectives were exploratory in nature. No formal hypothesis was tested since there were no well-substantiated priors regarding the expected direction of any potential differences between physician specialties. As such, two-sided tests of significance without adjustment for multiple comparisons were conducted. All analyses were performed using SAS® Version 9.2 (SAS Institute Inc., Cary, NC, USA).

Results
Physicians serving as study investigators in the REFLECTIONS observational study averaged 49.5 years of age with an average of 15.6 years in practice, with no notable differences across specialties (Table 1). Patients reported a mean age of 50.4 years and were mostly female and white. Patients enrolled by PCPs were more likely to be Hispanic (42.0%) than those enrolled by RHMs (4.2%) or OTHERs (16.7%).

Diagnosis and treatment of FM
Physician attitudes and beliefs
Physicians generally expressed confidence in their ability to diagnose (mean = 4.4 on a scale of 1 [completely disagree] to 5 [completely agree]) and treat FM with medications (mean = 4.3). All cohorts reported agreement on the use of the American College of Rheumatology (ACR) criteria to diagnose FM (mean = 4.0), and they agreed that recognizing (mean = 4.3) and treating (mean = 4.1) FM was their responsibility and that the psychological aspects of FM are important (mean = 4.5) (Figure 1A and B). All physician cohorts disagreed that the FM diagnosis was made in the absence of any other diagnosis (mean = 2.3) and disagreed with the notion that the symptoms of FM were of a psychosomatic origin (mean = 2.2). The RHMs reported significantly (P = 0.037) higher ratings than PCPs (4.5 versus 4.1) regarding their levels of confidence in diagnosing FM. The RHMs also reported significantly stronger agreement than OTHERs that they felt limited by the availability of adequate options for treating patients with FM (3.7 versus 2.9, P = 0.024).

Treatment
Pharmacologic treatments
Physicians reported using 182 unique medications for the treatment of FM. The top five prescribed medications were duloxetine, nonsteroidal anti-inflammatory drugs (NSAIDs), pregabalin, opioids (excluding tramadol), and tramadol. These
medications were generally the same across physician specialty (Table 2), although with some significant differences in their specific rank orderings. Pregabalin, which is one of the three FDA-approved medications for use in FM, was the most frequently prescribed medication by RHMs (28.8%) and was prescribed at a significantly higher rate than by PCPs (12.5%) or OTHERs (19.1%). The RHMs also prescribed duloxetine, another of the three FDA-approved medications for use in FM, significantly more often (27.1%) than PCPs (16.2%), though significantly less frequently than OTHERs (35.5%). The other approved FM medication at the time of the study, milnacipran, was less frequently prescribed than pregabalin or duloxetine overall, but again more frequently by RHMs (9.1%) and OTHERs (13.7%) than by PCPs (3.3%). The NSAIDs were the most frequently prescribed medication by PCPs (46.1%), at a rate approximately twice as often as RHMs (24.4%) or OTHERs (18.1%). OTHERs (32.8%) prescribed opioids significantly more often than did PCPs (19.2%) despite all physician cohorts rating the evidence in support of using opioids in FM as being modest. The highest ratings of perceived evidence in support of a medication for FM were given to duloxetine and pregabalin across all physician specialties.

Nonpharmacologic treatments
The most common nonpharmacologic treatments for FM were rest (91.0%) and exercise (89.5%), followed by heat modalities (75.5%) and prayer, relaxation, or meditation (75.2%). Patients of RHMs were significantly less likely to receive counseling (29.6%) than either patients of PCPs (37.6%) or OTHERs (46.5%) (Table 3). Patients of RHMs (18.8%) and OTHERs (23.4%) were more likely to have received transcutaneous electrical nerve stimulation unit treatment than patients of PCPs (11.4%), whereas patients of PCPs (15.1%) and OTHERs (12.4%) were more likely to have received acupuncture than patients of RHMs (6.3%). Patients of OTHERs were also more likely to have received trigger point injections than patients of PCPs or RHMs, and patients of OTHERs were more likely to have received chiropractic manipulation than patients of RHMs. Physicians strongly agreed that there was strong evidence in support of the use of patient education, with little variation across specialties. Both PCPs and OTHERs expressed more agreement than RHMs with respect to strong evidence supporting massage therapy in treating FM.

### Patient FM history and medical status
Compared with patients of OTHERs, the patients of RHMs and PCPs reported having seen significantly fewer health care providers for symptoms prior to receiving a FM diagnosis, and they also reported that fewer physicians were currently involved in their FM treatment (Table 4).
### Physician attitudes toward treating (A) and diagnosing (B) FM.

**Notes:** Results reflect mean of answers based on a 1–5 scale; 1 = completely disagree, 5 = completely agree. (A) *RHM*s vs OTHERs, $P$-value $= 0.02$. (B) *RHM*s vs PCPs, $P$-value $= 0.04$.

**Abbreviations:** ACR, American College of Rheumatology; FM, fibromyalgia; OTHERs, physicians practicing either pain or physical medicine, psychiatry, neurology, obstetrics and gynecology, osteopathy, or an unspecified specialty; PCPs, primary care physicians; RHMs, rheumatologists.

#### A
- **Long-term management of FM is another specialty’s responsibility**
  - 1.8
  - 3.2
  - 3.2
  - 3.2
  - 3.2
- **Practice has set guidelines for treating FM**
  - 3.0
  - 3.0
  - 3.0
  - 3.0
  - 3.0
- **Confident in treating FM with alternative therapies**
  - 3.4
  - 3.4
  - 3.4
  - 3.4
  - 3.4
- **Limited by availability of treatments for FM**
  - 3.6
  - 3.6
  - 3.6
  - 3.6
  - 3.6
- **Patient access to medications influences my treatment decisions**
  - 3.7
  - 3.7
  - 3.7
  - 3.7
  - 3.7
- **FM more difficult to treat than other pain**
  - 3.8
  - 3.8
  - 3.8
  - 3.8
  - 3.8
- **Treating FM is my responsibility**
  - 4.1
  - 4.1
  - 4.1
  - 4.1
  - 4.1
- **Believe in team approach to treating FM**
  - 4.2
  - 4.2
  - 4.2
  - 4.2
  - 4.2
- **Confident in treating FM with pharmacologic treatment**
  - 4.3
  - 4.3
  - 4.3
  - 4.3
  - 4.3

#### B
- **Symptoms patients suffer are psychosomatic**
  - 2.2
  - 2.2
  - 2.2
  - 2.2
  - 2.2
- **Diagnose FM in absence of other diagnoses**
  - 2.3
  - 2.3
  - 2.3
  - 2.3
  - 2.3
- **Diagnosis validates symptoms**
  - 3.9
  - 3.9
  - 3.9
  - 3.9
  - 3.9
- **I use ACR criteria to diagnose FM**
  - 4.0
  - 4.0
  - 4.0
  - 4.0
  - 4.0
- **FM patients take more time than average patient**
  - 4.2
  - 4.2
  - 4.2
  - 4.2
  - 4.2
- **Tender points are important in diagnosing FM**
  - 4.2
  - 4.2
  - 4.2
  - 4.2
  - 4.2
- **Recognizing FM is my responsibility**
  - 4.3
  - 4.3
  - 4.3
  - 4.3
  - 4.3
- **I am confident in diagnosing FM**
  - 4.4
  - 4.4
  - 4.4
  - 4.4
  - 4.4
- **Psychological aspects of FM are important**
  - 4.5
  - 4.5
  - 4.5
  - 4.5
  - 4.5
Table 2 Pharmacologic treatments for FM: patients’ use and physicians’ perceptions of evidence

<table>
<thead>
<tr>
<th>Patient use at baseline</th>
<th>RHMs n=1,130</th>
<th>PCPs n=271</th>
<th>OTHERs n=299</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duloxetine</td>
<td>306 (27.1)</td>
<td>106 (35.5)</td>
<td></td>
<td>0.001</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>276 (24.4)</td>
<td>54 (18.1)</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Pregabalin</td>
<td>325 (28.8)</td>
<td>57 (19.1)</td>
<td></td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Opioids</td>
<td>262 (23.2)</td>
<td>98 (32.8)</td>
<td></td>
<td>0.001</td>
</tr>
<tr>
<td>Tramadol</td>
<td>170 (15.0)</td>
<td>37 (12.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Benzodiazepines</td>
<td>176 (15.6)</td>
<td>45 (15.1)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SSRI s</td>
<td>178 (15.8)</td>
<td>21 (7.0)</td>
<td></td>
<td>0.011</td>
</tr>
<tr>
<td>Non-BZD/sedative/hypnotics</td>
<td>142 (12.6)</td>
<td>40 (13.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cyclobenzaprine</td>
<td>169 (15.0)</td>
<td>27 (9.0)</td>
<td></td>
<td>0.027</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>113 (10.0)</td>
<td>35 (11.7)</td>
<td></td>
<td>0.029</td>
</tr>
<tr>
<td>Milnacipran</td>
<td>103 (9.1)</td>
<td>41 (13.7)</td>
<td></td>
<td>0.05</td>
</tr>
<tr>
<td>Muscle relaxants</td>
<td>106 (9.4)</td>
<td>17 (5.7)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other antidepressants</td>
<td>87 (7.7)</td>
<td>15 (5.0)</td>
<td></td>
<td>0.022</td>
</tr>
<tr>
<td>Amtriptyline</td>
<td>63 (5.6)</td>
<td>13 (4.3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stimulants</td>
<td>43 (3.8)</td>
<td>31 (10.4)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other TCAs</td>
<td>59 (5.2)</td>
<td>1 (0.3)</td>
<td></td>
<td>0.020</td>
</tr>
</tbody>
</table>

Physician-reported agreement: “There is strong evidence in the literature to support pharmacological therapies in treating FM”

<table>
<thead>
<tr>
<th>Physician-reported survey response</th>
<th>RHMs n=54</th>
<th>PCPs n=25</th>
<th>OTHERs n=12</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average of 1–5 scale mean (SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duloxetine</td>
<td>4.2 (0.8)</td>
<td>3.4 (1.0)</td>
<td>4.2 (0.9)</td>
<td>0.003</td>
</tr>
<tr>
<td>NSAIDs</td>
<td>2.8 (1.1)</td>
<td>3.1 (1.0)</td>
<td>2.9 (1.1)</td>
<td></td>
</tr>
<tr>
<td>Pregabalin</td>
<td>4.4 (0.8)</td>
<td>4.1 (0.9)</td>
<td>4.4 (0.7)</td>
<td></td>
</tr>
<tr>
<td>Opioid analgesics</td>
<td>2.1 (1.1)</td>
<td>2.6 (1.0)</td>
<td>2.7 (1.0)</td>
<td></td>
</tr>
<tr>
<td>Tramadol</td>
<td>3.7 (0.8)</td>
<td>3.3 (0.7)</td>
<td>3.5 (0.8)</td>
<td></td>
</tr>
<tr>
<td>BZD hypnotics</td>
<td>2.4 (0.8)</td>
<td>2.5 (0.8)</td>
<td>2.5 (1.0)</td>
<td></td>
</tr>
<tr>
<td>SSRI s</td>
<td>3.7 (0.8)</td>
<td>3.7 (0.8)</td>
<td>3.5 (0.9)</td>
<td></td>
</tr>
<tr>
<td>Cyclobenzaprine</td>
<td>3.5 (0.7)</td>
<td>3.2 (0.9)</td>
<td>2.9 (0.8)</td>
<td>0.034</td>
</tr>
<tr>
<td>Gabapentin</td>
<td>3.4 (0.9)</td>
<td>3.6 (0.9)</td>
<td>3.3 (1.0)</td>
<td></td>
</tr>
<tr>
<td>Amtriptyline</td>
<td>3.8 (0.8)</td>
<td>3.9 (0.7)</td>
<td>3.0 (1.0)</td>
<td>0.003</td>
</tr>
<tr>
<td>TCAs</td>
<td>3.9 (0.7)</td>
<td>3.8 (0.8)</td>
<td>2.8 (1.0)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Venlafaxine</td>
<td>3.8 (0.9)</td>
<td>3.4 (0.8)</td>
<td>3.5 (0.7)</td>
<td></td>
</tr>
<tr>
<td>Trazadone</td>
<td>3.5 (0.9)</td>
<td>3.1 (0.9)</td>
<td>2.7 (1.1)</td>
<td>0.023</td>
</tr>
<tr>
<td>Melatonin</td>
<td>2.3 (0.9)</td>
<td>2.5 (0.9)</td>
<td>2.5 (1.0)</td>
<td></td>
</tr>
<tr>
<td>Growth hormone</td>
<td>2.0 (0.9)</td>
<td>2.0 (0.8)</td>
<td>2.3 (0.8)</td>
<td></td>
</tr>
</tbody>
</table>

Notes: (Top) Pharmacological treatment the patient has taken within the last 12 months including newly initiated and continuing therapies. (Bottom) Physician-reported agreement that there is strong evidence in the literature to support each of the following medications in the treatment of FM. Results reflect mean of answers based on a 1–5 scale; 1= completely disagree, 5= completely agree. “–” indicates not significant, P>0.05.

Abbreviations: BZD, benzodiazepine; FM, fibromyalgia; NSAIDs, nonsteroidal anti-inflammatory drugs; OTHERs, physicians practicing either pain or physical medicine, psychiatry, neurology, obstetrics and gynecology, osteopathy, or an unspecified specialty; PCPs, primary care physicians; RHMs, rheumatologists; SD, standard deviation; SSRI s, selective serotonin uptake inhibitors; TCAs, tricyclic antidepressants.

Patients from the REFLECTIONS study experienced an average of six concomitant chronic medical conditions (range: 0–25 conditions) within the 3 years prior to study enrollment. Patients of RHMs reported significantly lower incidences of depression, sleep disorders, anxiety, and chronic fatigue syndrome than did patients of PCPs (P<0.001) (Table 4). Patients of RHMs also reported significantly lower percentages of several other chronic conditions, compared with patients of OTHERs.

Discussion

In this study, we sought to identify consistencies and variations in physician and practice characteristics and attitudes toward diagnosing and treating FM using data from the REFLECTIONS study. Results from this study suggested that PCPs and RHMs shared generally similar personal and practice profile characteristics. Most investigators in the REFLECTIONS study were RHMs, followed by PCPs and OTHERs, which is consistent with the historical view that
FM is a rheumatologic condition.1-7 There were differences in the racial composition of patients by physician specialty, but this is likely due to the disproportionate numbers of study physicians in Puerto Rico practicing as PCPs.

Both RHMs and PCPs in our study agreed on evidence supporting nonpharmacological therapies in treating FM such as patient education, exercise, and cognitive behavioral therapy, which is consistent with other studies that have also reported that FM treatment should involve nonpharmacologic as well as pharmacologic treatments.8,9

Physicians from all cohorts reported using ACR criteria to guide their diagnosis of FM, intimating that specialists other than RHMs are also aware that FM can be positively diagnosed using 1990 ACR guidelines.7 While both RHMs and PCPs in this study generally expressed high levels of confidence in their ability to recognize and diagnose FM, the RHMs were significantly more confident than PCPs in their ability to diagnose FM. Increasing reliance upon 2010 ACR criteria which emphasize the assessment of patient symptoms over the tender point counts that played an important role in the 1990 ACR criteria may serve to close this gap in diagnostic confidence.10

Other studies have also suggested that PCPs are as equipped as specialists in the management of FM.11,12 Contrary to these findings, however, some studies13,14 have reported that the diagnosis and management of FM might pose a challenge to non-RHM specialists. Among Canadian physicians, 36% of general practitioners and 25% of specialists (anesthesiologists, neurologists, physiatrists, psychiatrists, and RHMs) expressed doubts in their ability to diagnose FM.14 In another study of physicians in Europe, Mexico, and South Korea, up to 61% of PCPs compared with 31% of RHMs found it difficult to diagnose FM.15 Much of this seeming discrepancy likely reflects differences between the composition of the physician samples used in the

Table 3 Nonpharmacologic treatments for FM: patients’ use and physicians’ perceptions of evidence

<table>
<thead>
<tr>
<th>Treatment</th>
<th>RHMs</th>
<th>PCPs</th>
<th>OTHERs</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=1,130</td>
<td>n=271</td>
<td>n=299</td>
<td></td>
</tr>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
<td>n (%)</td>
<td></td>
</tr>
<tr>
<td>Rest</td>
<td>1,031 (91.2)</td>
<td>237 (87.5)</td>
<td>279 (93.3)</td>
<td></td>
</tr>
<tr>
<td>Exercise</td>
<td>1,018 (90.1)</td>
<td>231 (85.2)</td>
<td>272 (91.0)</td>
<td></td>
</tr>
<tr>
<td>Heat modalities</td>
<td>870 (77.0)</td>
<td>189 (69.7)</td>
<td>225 (75.3)</td>
<td>0.038</td>
</tr>
<tr>
<td>Prayer, relaxation, meditation</td>
<td>851 (75.3)</td>
<td>194 (71.6)</td>
<td>234 (78.3)</td>
<td></td>
</tr>
<tr>
<td>Distraction</td>
<td>800 (70.8)</td>
<td>180 (66.4)</td>
<td>205 (68.6)</td>
<td></td>
</tr>
<tr>
<td>Cold therapy</td>
<td>467 (41.3)</td>
<td>111 (41.0)</td>
<td>136 (45.5)</td>
<td></td>
</tr>
<tr>
<td>Counseling (including CBT)</td>
<td>334 (29.6)</td>
<td>102 (37.6)</td>
<td>139 (46.5)</td>
<td>0.030</td>
</tr>
<tr>
<td>Massage, reflexology</td>
<td>366 (32.4)</td>
<td>90 (33.2)</td>
<td>134 (44.8)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Trigger point injections</td>
<td>290 (25.7)</td>
<td>65 (24.0)</td>
<td>111 (37.1)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Chiropractic manipulation</td>
<td>246 (21.8)</td>
<td>64 (23.6)</td>
<td>93 (31.1)</td>
<td>0.002</td>
</tr>
<tr>
<td>TENS unit</td>
<td>215 (18.8)</td>
<td>31 (11.4)</td>
<td>70 (23.4)</td>
<td>0.012</td>
</tr>
<tr>
<td>Acupuncture</td>
<td>71 (6.3)</td>
<td>41 (15.1)</td>
<td>37 (12.4)</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Physician-reported agreement: “There is strong evidence to support nonpharmacological therapies in treating FM”

<table>
<thead>
<tr>
<th>Treatment</th>
<th>RHMs</th>
<th>PCPs</th>
<th>OTHERs</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=54</td>
<td>n=25</td>
<td>n=12</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Average of 1–5 scale mean (SD)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient education</td>
<td>4.6 (0.6)</td>
<td>4.3 (0.7)</td>
<td>4.3 (0.7)</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular exercise</td>
<td>4.2 (0.7)</td>
<td>4.0 (0.8)</td>
<td>3.6 (1.0)</td>
<td></td>
</tr>
<tr>
<td>CBT</td>
<td>3.8 (0.6)</td>
<td>3.7 (0.8)</td>
<td>3.6 (1.0)</td>
<td></td>
</tr>
<tr>
<td>Biofeedback</td>
<td>3.3 (0.7)</td>
<td>3.2 (0.7)</td>
<td>3.3 (0.8)</td>
<td></td>
</tr>
<tr>
<td>Massage</td>
<td>2.9 (0.9)</td>
<td>3.5 (0.8)</td>
<td>3.6 (0.9)</td>
<td></td>
</tr>
<tr>
<td>Acupuncture</td>
<td>2.9 (0.9)</td>
<td>3.0 (0.9)</td>
<td>2.8 (1.1)</td>
<td>0.010</td>
</tr>
<tr>
<td>Hypnotherapy</td>
<td>2.2 (0.7)</td>
<td>2.7 (0.6)</td>
<td>2.8 (0.9)</td>
<td>0.036</td>
</tr>
<tr>
<td>Electrotherapy</td>
<td>2.4 (0.8)</td>
<td>2.5 (0.7)</td>
<td>2.3 (0.9)</td>
<td>0.033</td>
</tr>
</tbody>
</table>

Notes: (Top) Nonpharmacologic treatments for FM during 12 months prior to study enrollment. (Bottom) Physician-reported agreement that there is strong evidence in the literature to support each of the following interventions in the treatment of FM. Results reflect mean of answers based on a 1–5 scale: 1= completely disagree, 5= completely agree. “=” indicates not significant, \( P=0.05 \).

Abbreviations: CBT, cognitive behavioral therapy; FM, fibromyalgia; OTHERs, physicians practicing either pain or physical medicine, psychiatry, neurology, obstetrics and gynecology, osteopathy, or an unspecified specialty; PCPs, primary care physicians; RHMs, rheumatologists; SD, standard deviation; TENS, transcutaneous electrical nerve stimulation.
Table 4 Patient clinical status at baseline

<table>
<thead>
<tr>
<th>Fibromyalgia history</th>
<th>Patients of:</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RHMs n=1,130</td>
<td>PCPs n=271</td>
</tr>
<tr>
<td></td>
<td>RHMs vs PCPs</td>
<td>RHMs vs OTHERs</td>
</tr>
<tr>
<td>Years since first FM symptoms, mean (SD)</td>
<td>10.0 (9.2)</td>
<td>9.5 (8.3)</td>
</tr>
<tr>
<td>Years since first FM diagnosis, mean (SD)</td>
<td>5.6 (6.4)</td>
<td>5.3 (5.6)</td>
</tr>
<tr>
<td>How many HCPs seen for symptoms before FM diagnosis, mean (SD)</td>
<td>3.5 (5.6)</td>
<td>3.1 (3.5)</td>
</tr>
<tr>
<td>How many HCPs currently involved in FM treatment, mean (SD)</td>
<td>1.6 (1.3)</td>
<td>1.5 (0.9)</td>
</tr>
</tbody>
</table>

"Chronic medical problems present during the 3 years prior to study enrollment: n (%)"

| Back pain                                           | 888 (80.7)    | 223 (82.9)   | 246 (83.4)     | –         | –         | –         |
| Irritable bowel syndrome                            | 404 (37.9)    | 98 (36.7)    | 125 (42.8)     | –         | –         | –         |
| Abdominal pain                                       | 380 (35.3)    | 100 (37.3)   | 124 (42.3)     | –         | –         | –         |
| Asthma                                              | 239 (22.2)    | 66 (24.4)    | 59 (20.1)      | –         | –         | –         |
| Rheumatoid arthritis                                | 147 (13.9)    | 24 (9.0)     | 38 (13.1)      | –         | –         | –         |
| Temporomandibular joint disorder                    | 228 (21.6)    | 51 (19.5)    | 67 (23.4)      | –         | –         | –         |
| Ulick                                               | 89 (8.4)      | 27 (10.1)    | 31 (10.6)      | –         | –         | –         |
| Heart disease                                        | 89 (8.3)      | 25 (9.3)     | 18 (6.2)       | –         | –         | –         |
| Depression                                           | 628 (57.7)    | 209 (78.3)   | 220 (74.1)     | <0.001    | <0.001    | –         |
| Arthritis                                            | 709 (65.0)    | 170 (62.7)   | 146 (49.2)     | –         | <0.001    | 0.003     |
| Sleep disorders                                      | 574 (53.5)    | 191 (72.3)   | 189 (64.3)     | <0.001    | 0.003     | –         |
| Anxiety                                              | 563 (52.0)    | 181 (67.5)   | 202 (68.2)     | <0.001    | <0.001    | –         |
| Chronic fatigue syndrome                            | 407 (38.2)    | 160 (60.4)   | 157 (53.6)     | <0.001    | <0.001    | –         |
| Migraine                                             | 387 (36.0)    | 101 (38.0)   | 132 (45.1)     | –         | 0.014     | –         |
| Hypertension                                         | 387 (35.8)    | 112 (41.9)   | 84 (29.0)      | –         | –         | 0.004     |
| Diabetes                                             | 114 (10.6)    | 38 (14.2)    | 23 (7.9)       | –         | –         | 0.050     |

Notes: “–” indicates not significant, *P<0.05; "chronic medical problems reported by >5% of patients in any cohort.

Abbreviations: FM, fibromyalgia; HCPs, health care providers; OTHERs, physicians practicing either pain or physical medicine, psychiatry, neurology, obstetrics and gynecology, osteopathy, or an unspecified specialty; PCPs, primary care physicians; RHMs, rheumatologists; SD, standard deviation.

referred studies and investigators was in the REFLECTIONS trial. Related to this finding was the fact that physicians across specialties in this study generally acknowledged that recognizing and treating FM was their responsibility, which suggests that at least a segment of the PCP population in the United States is caring for patients with FM themselves rather than: 1) routinely steering patients suspected of having FM to RHMs; or 2) approaching the condition as being purely musculoskeletal in nature.15

All cohorts disagreed that the FM diagnosis was made in the absence of other diagnoses, indicating that behavior of the physicians in this study is consistent with a proposal by Shir and Fitzcharles15 that emphasized that FM diagnosis should be based on a positive clinical diagnosis rather than on the exclusion of all other possibilities. The physicians in this study also showed strong agreement that the psychological aspects of FM are important, but did not agree that the symptoms were of psychosomatic origin, consistent with the notion that the symptoms of FM are “real” and that pain can be present in the absence of a readily measurable clinical abnormality.7,16

Even though most physicians were more confident in prescribing pharmacological therapies, physicians tended to endorse a multidisciplinary approach to managing FM with a combination of pharmacologic and nonpharmacologic treatment modalities, similar to findings reported in previous studies.17,18 Significantly fewer patients of RHMs versus PCPs and RHMs versus OTHERs reported use of counseling and acupuncture for the treatment of FM in the year before study enrollment. There was a statistically significant difference across physician specialty where RHMs, compared with OTHERs, felt more limited by the availability of treatment options for patients with FM; RHMs less often reported support for the use of massage, compared with PCPs and OTHERs, and the use of hypnotherapy compared with OTHERs. This may be due to a lack of familiarity or comfort in implementing newer, less traditional nonpharmacologic measures into routine rheumatology practice. However, this may also reflect the smaller number of patients in the group of OTHERs and may not be clinically relevant.

The physicians accepted responsibility for the long-term management of their patients with FM and also expressed the belief that a team approach to treating FM was appropriate. Despite the existence of evidence-based treatment guidelines (American Pain Society in 2005;19 European League Against...
Rheumatism in 2008), physicians were generally neutral about using set guidelines for treating FM.

Differences between these categories of physicians reinforce previously existing evidence that there is no universally agreed-upon intervention or treatment strategy/mix for treating all patients with FM. The PCPs and RHMs agree on the same top five recommended pharmacological treatments, but vary somewhat in their ordering within these top five treatments. The most commonly used pharmacologic treatments across all provider specialty groups included duloxetine, NSAIDs, pregabalin, and opioids. Patient symptoms related to clinical characteristics of severity of pain, depression, anxiety, disability, cognition, sleep disturbances, and fatigue were not significantly associated with treatment decisions. Treatment patterns may reflect current changes in the environment with the entry of pregabalin in June 2007 and duloxetine in June 2008 (just before the start of the study).

Current guidelines indicate strong evidence to support use of tricyclic antidepressants, duloxetine, milnacipran, pregabalin, and gabapentin for the treatment of FM. RHMs were considerably more likely to prescribe each of the three FDA-approved medications (duloxetine, pregabalin, and milnacipran) than were PCPs, suggesting that RHMs may be more familiar with recent guidelines and newly approved medications. Despite the apparent use of NSAIDs and opiates across specialties in this study, evidence for the efficacy of NSAIDs and opiates in patients with FM is lacking.

In REFLECTIONS, use of NSAIDs was relatively high, but especially for patients of PCPs versus RHMs. This difference may be the result of greater non-FM pain-related comorbidities, and greater perceived need for direct treatment of specific comorbid symptoms in patients of PCPs. It could also be a response to patient preference or request for medication which, while lacking evidence, may be perceived as helpful to the individual patient. Use of opioids was higher in OTHERs than in PCPs, perhaps reflecting a more conservative stance among PCPs who are more likely to be involved in the long-term management of FM.

Notable was the small percentage of patients reporting the use of amitriptyline and other tricyclic antidepressants in comparison with the strong recommendations in favor of these medications in published guidelines and other studies. Similarly, physicians did not express strong agreement about their use. Benzodiazepines were also among the more frequently used medications in our study. Benzodiazepines and nonbenzodiazepine sedatives may have been prescribed more for their roles in sleep disturbances rather than for FM specifically.

Limitations
The study findings may not truly reflect a broad view of physician specialties that treat patients with FM for several reasons. The patients and physicians may not have been nationally representative even though the sample was large and included patients from 26 states and Puerto Rico. Most participating physicians were RHMs or PCPs who may have had greater interest and/or expertise in treating FM than OTHERs, including pain and physical medicine specialists, who were sparsely represented. The study was unable to tease out differences in physician treatment choices due to symptom severity. However, other, unmeasured factors may impact these differences. As indicated in the “Methods” section, the sample size for the group of OTHERs is too small and heterogeneous to draw conclusions from, but rather is included for completeness. In addition, the sample of providers is skewed towards male providers and RHMs, which may limit the generalizability of the results. Patients could be at any stage in the management cycle for FM; therefore, these findings may not be applicable to newly diagnosed patients with FM. There may be an increase in experimentwise type I error rate as no adjustments were made to account for making multiple pairwise comparisons.

Conclusion
The main findings in this study were that all groups of physicians seemed confident in their diagnosis of FM and see management of FM as their responsibility. RHMs are more likely to use the currently recommended therapies, with PCPs more often prescribing more traditional therapies. All groups of physicians use a mixture of pharmacological and nonpharmacological modalities. With FM being categorized as more of a pain syndrome rather than a musculoskeletal disease, and as the care of patients with FM shifts from RHMs to multiple physician specialties, examining predictors of FM treatment selection such as physician specialty may help improve FM treatment selection.

Acknowledgments
This study was funded through Eli Lilly and Company (Indianapolis, IN, USA). We thank Deborah D’Souza, PhD, from inVentiv Health Clinical, LLC, for assistance with the preparation of the manuscript. Bill H McCarberg is retired from the Chronic Pain Management Program for Kaiser Permanente, Kaiser Permanente, and the Southern California Permanente Medical Group, Escondido, CA, USA.
Disclosure

Stephen L Able, Rebecca L Robinson, and Madelaine Wohlreich are employees of, and minor shareholders in, Eli Lilly and Company. Kurt Kroenke is a consultant for Eli Lilly and Company. Philip Mease receives research funding, consulting fees, and is an honoraria speaker for Eli Lilly and Company and Pfizer, and receives research funding from Forest Pharmaceuticals. David A Williams is a consultant for Eli Lilly and Company. Yi Chen is a former employee of inVentiv Health Clinical. Bill H McCarberg is an advisor to Iroko, Pfizer, Zogenix, Collegium, Millennium, Mallinckrodt, Inspirin, Salix, Takeda, Depomed, Janssen, Kaleo, and AstraZeneca, and has the following stock holdings: Johnson and Johnson, Protein Design Labs, Biospecifics Technologies, Nektar Therapeutics, and Galena.

References